TEVA241115P17500
- 0.55
- +0.08+17.02%
Teva Pharmaceutical Industries Newsroom
Assertio Stock Gains Amid Clash With Activist Investor, Q3 Earnings
UBS Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Maintains Target Price $26
Teva to Present at the Jefferies London Healthcare Conference
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
UBS Downgrades Teva Pharmaceutical Industries(TEVA.US) to Hold Rating, Maintains Target Price $26
US MOVERS&SHAKERS Nov 04-Nov 08, 2024
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $25
10-Q: Q3 2024 Earnings Report
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript Summary
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Express News | Teva Pharm CEO Francis Says Expects Generics Prices to Be Pushed Down in 2025
Express News | Teva Pharm CEO Francis Says We Think We Have a "Good Case" in Appeal Against European Commission Fine, Appeal Likely to Take Many Years
Teva Gains After Raising Outlook for Second Time This Year
Express News | Teva Pharm CEO Francis Says on Track to Meet Growth Targets by 2027 of Revenue Growth, Operating Margin and Net Debt/Ebitda
Express News | Teva Pharm CEO Francis Says Divestment of Teva APi on Target for First Half of 2025
Express News | Teva Pharm CEO Francis Says We Are Driving Strong Performance Due to Our Branded Drugs
Press Release: Medincell: 25% Raise in 2024 UZEDY(R) Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3